Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: aprea.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2021 | Neutral → Underweight | JP Morgan | |
| 8/16/2021 | Buy → Hold | Berenberg | |
| 8/16/2021 | $6.00 → $4.00 | Neutral | HC Wainwright & Co. |
| 8/13/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
| 8/13/2021 | $5.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |